Source:http://linkedlifedata.com/resource/pubmed/id/11506466
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
2001-8-16
|
| pubmed:abstractText |
The carbohydrate antigen 19-9 (CA 19-9), a determinant (sialylated lacto-N-fucopentaose 119) of a circulating oligosaccharide antigen, is a frequently used tumor marker. Echinococcus spp. infects humans throughout the world and may be able to synthesize closely related molecules which could interfere with the measurement and interpretation of CA 19-9 concentration. The main objective of the present study was to determine the range of CA 19-9 levels in the sera of patients infected by E. granulosus (cystic hydatide disease; CYSHD) or E. multilocularis (alveolar hydatide disease; ALVHD). Serum samples were collected from patients (aged 10-85 years) over a period of 5 years: from 19 patients with CYSHD and from 20 patients with ALVHD. Infection was confirmed by positive Echinococcus serology and clinical evidence provided by imaging and/or histopathological findings. CA 19-9 was detectable in 13 patients with CYSHD (13.5 +/- 8.5 kU/l) and 13 patients with ALVHD (30.0 +/- 21 kU/l; p < 0.05). Thus ALVHD patients exhibited a significantly higher plasma level of CA 19-9 than CYSHD patients. The serum level of CA 19-9 assessed with an increased cut-off value (> 22 kU/l) was elevated in nine (45%) of 20 ALVHD patients compared to two (11%) of 19 CYSHD patients (p < 0.05). Sera from patients with Echinococcus multilocularis infection contain substances which cross-react with CA 19-9. These substances originate either from the parasite or are synthesized by the host in response to the infection, and possibly bear the Lewis-a antigen or closely related structures which are recognized by anti-CA 19-9 antibodies. Our findings are relevant to the investigation of patients presenting with cystic lesions for which the differential diagnosis includes an infectious or neoplastic origin.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
1434-6621
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
39
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
527-30
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:11506466-Adolescent,
pubmed-meshheading:11506466-Adult,
pubmed-meshheading:11506466-Aged,
pubmed-meshheading:11506466-Aged, 80 and over,
pubmed-meshheading:11506466-Animals,
pubmed-meshheading:11506466-Antigens, Helminth,
pubmed-meshheading:11506466-CA-19-9 Antigen,
pubmed-meshheading:11506466-Child,
pubmed-meshheading:11506466-Cross Reactions,
pubmed-meshheading:11506466-Diagnosis, Differential,
pubmed-meshheading:11506466-Echinococcosis,
pubmed-meshheading:11506466-Echinococcosis, Hepatic,
pubmed-meshheading:11506466-Echinococcus,
pubmed-meshheading:11506466-Female,
pubmed-meshheading:11506466-Humans,
pubmed-meshheading:11506466-Lewis Blood-Group System,
pubmed-meshheading:11506466-Liver Diseases,
pubmed-meshheading:11506466-Male,
pubmed-meshheading:11506466-Middle Aged
|
| pubmed:year |
2001
|
| pubmed:articleTitle |
Elevated carbohydrate antigen 19-9 (CA 19-9) in patients with Echinococcus infection.
|
| pubmed:affiliation |
Department of Medicine, University of Bern, Switzerland.
|
| pubmed:publicationType |
Journal Article
|